Moderna : Publication FY de bonne facture – guidance 2024 confirmée
>Résultats 2023 au-dessus des attentes - Moderna a publié hier ses résultats du T4 2023 dont les ventes ressortent à 2.8 Md$ (vs 2.5 Md$ att.), sachant que les ventes annuelles (6.8 Md$) avaient été préalablement publiées. Comme attendu, les ventes de Spikevax ont fortement diminué (-43%), principalement en raison de la baisse du volume. Sur le plan opérationnel, l’EBIT ressort à 6 M$ (vs -480 M$ att.) bénéficiant d’une diminution des COGS (-52% ; -990 M$) partiellem...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.